Ivermectin Can't Cure Cancer
A new preprint circulating online alleges that a combination of ivermectin and mebendazole can cure cancer, a claim promoted by the unregulated Wellness Company. The paper is a survey of patients at the company’s clinics and offers no clinical trial data to substantiate efficacy. While laboratory studies suggest these antiparasitic drugs affect cancer cells in vitro, there is no evidence they improve outcomes in human patients. The article underscores the persistence of ivermectin‑related misinformation despite its proven lack of benefit for COVID‑19.
Daily Bulletin...
President Donald Trump formally withdrew Dr. Casey Means’ nomination for U.S. Surgeon General after the Senate stalled her confirmation. In her place, the White House tapped Fox News health commentator Nicole Saphier as the new nominee. Means, a former COVID‑19...
Medical School Rankings Reshape What They Measure
U.S. News & World Report’s medical‑school rankings have long guided applicants, but recent withdrawals by elite institutions such as Harvard, Columbia, Stanford, Penn and Mount Sinai expose deep flaws. Critics argue the current tiered model over‑weights research funding, MCAT scores...
Independent Doctors Applaud President Trump and the White House for Surgeon General Nominee Dr. Nicole Saphier
President Trump nominated radiologist and bestselling author Dr. Nicole Saphier as U.S. Surgeon General, prompting applause from the Independent Medical Alliance (IMA), the nation’s largest coalition of independent physicians. The IMA praised Saphier’s patient‑first advocacy and her willingness to challenge...
Justices Poised to Protect Generics Manufacturers From Liability for Decisions of Pharmacists About Prescribing Their Products
The Supreme Court heard arguments in Hikma Pharmaceuticals USA v. Amarin Pharma, where Amarin seeks to hold generic maker Hikma liable for pharmacists dispensing its generic product in ways that infringe Amarin’s Vascepa patents. The Court appeared skeptical that Hikma’s...
Top Psychiatrist Drops Bombshell Testimony: Canadian Government QUIETLY EUTHANIZING MENTALLY ILL PATIENTS
Renowned psychiatrist Dr. John Maher testified before a Canadian parliamentary committee that the Medical Assistance in Dying (MAiD) program is already being applied to patients with severe mental illness, often under dubious clinical justifications. He cited specific cases, including a...
Oklahoma: As if Work Reporting Won't Cause Enough Damage, GOP Moves to Kill Off Medicaid Expansion Entirely
Oklahoma's Republican legislature is advancing House Bill 4440 and House Joint Resolution 1067 to remove Medicaid expansion from the state constitution and either shift it to statutory law or repeal it entirely. Both measures cleared the Senate Rules Committee along...
The CDC Says It Is “Following the Evidence.” So Why Hide the Evidence?
The CDC, under acting director Jay Bhattacharya, declined to publish a Morbidity and Mortality Weekly Report that found COVID‑19 vaccination cut emergency‑room visits and hospitalizations by roughly half during the last winter. HHS cited methodological flaws in the study’s test‑negative...
Who Is Nicole Saphier?
President Trump withdrew Casey Means and, within minutes, nominated Dr. Nicole B. Saphier, a breast‑imaging oncologist at Memorial Sloan Kettering, as his third Surgeon General pick in fifteen months. Saphier is the author of the 2020 bestseller *Make America Healthy...
The Prostate Cancer Recovery Few Men Are Warned About
Physiatrist Dr. Francisco M. Torres, a prostate‑cancer survivor, recounts his unexpected post‑operative challenges after robot‑assisted radical prostatectomy. His experience revealed a systemic failure: patients receive scant guidance on pre‑habilitation and pelvic‑floor rehabilitation, despite strong evidence that these interventions improve continence...
Asembia ASX26: The Strain on the Development of Infrastructure for Sustainable C&G Therapy
Cell and gene therapies promise transformative treatments but remain hampered by steep costs across research, manufacturing, and delivery. At the Asembia ASX26 Summit, Aradigm Health CEO Will Shrank highlighted the fragmented U.S. payment landscape as a core barrier to sustainable...
Cigna Sez Sayonara: Another Major Carrier Bailing on ACA Exchanges Next Year
Cigna announced it will exit the individual health‑insurance market under the Affordable Care Act in 2027, leaving roughly 369,000 members in 11 states to find new coverage. The move follows a 17% year‑over‑year drop in Cigna’s ACA enrollment, even as...
All Eyes on Fauci as Top Aide Indicted Over Scheme to Hide COVID Emails
Former NIAID senior adviser Dr. David Morens was indicted on federal charges for conspiring to hide COVID-19-related communications by using private Gmail accounts and deleting records. Prosecutors allege he created a backchannel to Dr. Anthony Fauci to evade FOIA requests...
Pharma Pulse: The Ember Cube 2 and a $1 Trillion Prescription Spending Projection for 2026
Ember LifeSciences unveiled the Ember Cube 2, a modular cold‑chain solution with real‑time monitoring, GPS tracking and cloud visibility, earning a Red Dot “Best of the Best” award. At the Asembia AXS26 summit, policy experts warned that new pricing legislation is compressing post‑launch...
Physician Career Choices Come Down to Risk Tolerance
Physician career decisions often hinge on risk tolerance, with most doctors opting for stable, modest pay raises (Career A) rather than high‑potential, uncertain roles (Career B). Dr. Stanley Liu argues that a robust financial plan—tax optimization, reserve funds, debt strategies, and contract...
FDA Moves to Speed Review Support for Psychedelic-Related Treatments
The FDA announced a new fast‑track mechanism for psychedelic‑based therapies, issuing Commissioner’s National Priority Vouchers to three programs targeting depression and PTSD with psilocybin or methylone. It also granted an IND for DemeRx NB to study noribogaine hydrochloride as a...
Varenicline
Varenicline (Chantix) received FDA approval in 2006 as a partial α4β2 nicotinic receptor agonist, offering a middle‑ground approach between nicotine replacement and bupropion. Its mechanism delivers enough receptor activation to ease cravings while antagonizing nicotine’s rewarding effects. The drug quickly...
Shared Responsibility in Patient Care Needs Boundaries
Physicians often end visits with vague advice such as “call if things get worse,” leaving patients without clear criteria for escalation. Dr. Alan F. Feren argues that shared responsibility in care requires explicit boundaries that define what constitutes worsening symptoms, time...
Guidance Breakdown: FDA Proposes Pulling Back on Premarket Requirements for NIOSH-Approved Respirators
On April 20, the FDA released draft guidance proposing to deprioritize most pre‑market requirements—registration, listing, 510(k), labeling, MDR, and UDI—for NIOSH‑approved respirators used for medical purposes. The policy would cover surgical N95s, other NIOSH‑approved respirators, and public‑use filtering facepiece respirators, while...
How Advanced Mammography Viewers Are Shaping the Future of Breast Cancer Detection
Advanced mammography viewers are delivering sharper, lower‑noise images that help radiologists spot cancers, especially in dense breast tissue. Yet the industry’s biggest hurdle is integrating these tools into real‑world workflows, where speed, usability, and system compatibility dictate whether improved visuals...
The AI Toolkit for Advocating for a Loved One in the Hospital (4 Prompts Plus Privacy Rules)
The post introduces a practical AI toolkit that helps non‑clinical family members advocate for hospitalized loved ones. It outlines three privacy rules, three verification rules, and provides four ready‑to‑use AI prompts designed to generate evidence‑based questions for clinicians. The author...
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck announced the first patient has been dosed in its global Phase 3 ELOWEN program, testing the oral TLR7/8 inhibitor enpatoran in lupus patients with active skin manifestations. The double‑blind, placebo‑controlled studies—ELOWEN‑1 and ELOWEN‑2—will enroll roughly 200 participants each across 266...
Artificial Intelligence in Residency Education and Family Medicine
A 2024 survey revealed that 75% of medical students have had no formal AI training, while two‑thirds of practicing physicians already use AI—a 78% jump from the prior year. Family medicine residency programs are now confronting how to embed AI...
Elevance Health’s Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
Elevance Health’s affiliated plans are tackling rising small‑business health costs with two innovative models: Balanced Funding and Multiple Employer Welfare Arrangements (MEWAs). Balanced Funding guarantees a fixed monthly payment while capping risk, rewarding employers when actual claims fall below expectations....
CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market...
CGT Global announced the appointment of Charlotte Ivancic to its Board of Advisors, bringing over 25 years of federal health policy and legislative experience. Ivancic, a partner at FGS Global and former senior aide to Senate Majority Leader Bill Frist,...
What We Know (and Don’t Know) About Peptide Safety
Peptide safety is neither automatically assured by mimicking endogenous hormones nor inherently hazardous because research is incomplete. The risk profile depends on the specific peptide, the depth of clinical evidence, product purity, and real‑world usage conditions. Early‑phase trials provide maximum...
Should Depression Be on the Same Checklist as Smoking and Diabetes?
A propensity‑matched analysis of 11,570 elective single‑level lumbar fusion patients found that preoperative major depressive disorder (MDD) does not raise reoperation, mortality, or early emergency‑department visits. However, the same cohort showed markedly higher rates of new psychiatric diagnoses, somatic symptom...
Independent Medical Practice Runs on Operations
Independent physicians are finding that clinical training leaves them unprepared for the operational hurdles that determine a practice’s survival. Credentialing delays of 90‑180 days can stall cash flow while rent, payroll and software costs continue. Without specialty‑specific benchmarks, practices struggle...
The FDA Real Time Clinical Trial Announcement Quietly Dissolves Phase Gates, Breaks Biotech Capital Markets Plumbing, and Opens a Founder...
The FDA announced on April 28 that real‑time clinical trials (RTCTs) are now live, with AstraZeneca’s phase‑2 lymphoma study and Amgen’s phase‑1b small‑cell lung cancer trial streaming data through Paradigm Health. The agency claims a 20‑40 % reduction in development timelines, but...
IBS News Flash. Late Night Eating + Stress = Bowel Dysfunction
A study presented at Digestive Disease Week found that eating late at night while experiencing high stress nearly doubles the odds of constipation or diarrhea, affecting roughly 40% of participants with both habits. The same combination was linked to reduced...
Qp:Qs = 2.29. Now What?
The post highlights that calculating a Qp:Qs ratio of 2.29 is straightforward, but interpreting it correctly is where most sonographers stumble. Without the broader clinical picture, the ratio can misguide diagnosis and treatment planning. The author promises a step‑by‑step guide...
Hemab Therapeutics (COAG) IPO Deck
Hemab Therapeutics, a clinical‑stage biotechnology firm, announced its IPO deck on April 30, 2026. The company focuses on innovative therapies for rare blood‑coagulation disorders, including both bleeding and thrombotic conditions. Its pipeline features two Phase 2 candidates targeting hemophilia and antiphospholipid syndrome, and...
Xtalks Featured Member: Ravindra Kumar, Medical Technologist, PGIMER, Chandigarh
Ravindra Kumar, a medical technologist at PGIMER in Chandigarh, has been highlighted by Xtalks for his work in MRI optimization and radiation dose reduction. He recently completed a phantom‑based chest CT study that improved image quality while lowering patient exposure,...
Xtalks Featured Member: Parminder Singh Bhasin, Senior Director, Head of Analytical Research and Project Management, Intech Biopharm. Ltd
Parminder Singh Bhasin, Senior Director at Intech Biopharm Ltd., has been highlighted as an Xtalks Featured Community Member. With more than 26 years in pharmaceutical R&D, he oversees analytical research, method validation, and project management for complex generics, pMDI, nasal...
Xtalks Featured Member: Laura Saltonstall, VP, Medical Affairs, Immunology, Sobi
Xtalks spotlighted Dr. Laura Saltonstall, Vice President of Medical Affairs for Immunology at biotech firm Sobi. Drawing on her clinical background and personal experience as a parent of a child with a rare genetic disorder, she drives patient‑centered strategies that...
A Combination Treatment Is Claimed to Produce Sizable Life Extension in Aged Mice
Seragon funded a pre‑clinical trial of SRN‑901, a proprietary oral cocktail that blends urolithin A, quercetin, nicotinamide riboside, alpha‑lipoic acid and the company’s SRN‑820. In 18‑month‑old mice on a Western diet, the regimen extended median remaining lifespan by 33% and cut...
What If the First Sign of Alzheimer's Isn't Forgetting?
Neuroscientists discovered that Master Sommeliers have a thicker entorhinal cortex, a brain region that deteriorates early in Alzheimer’s. Large cohort studies show rapid decline in smell identification predicts dementia risk comparable to the APOE‑ε4 gene. Imaging links poorer olfactory performance...
Alesi Surgical Secures £7m to Tackle Hazardous Surgical Smoke in Operating Theatres, Led by IW Capital
Alesi Surgical announced a £7 million (≈ $9 million) funding round led by IW Capital, aimed at scaling its FDA‑approved Ultravision2 smoke‑management platform worldwide. The technology uses electrostatic precipitation to eliminate surgical smoke up to 225‑times faster than conventional suction, improving visibility and...
Seaport Therapeutics (SPTX) IPO Deck
Seaport Therapeutics, a clinical‑stage biotech firm, is preparing an initial public offering to fund its oral drug program targeting major neuropsychiatric conditions such as depression and anxiety. The company’s IPO deck emphasizes a “proven path” in neuroscience, highlighting pre‑clinical data...
The Biotech Bi-Weekly: A Virtual Biology Initiative, a New Discovery Grant and a Protein Supplier to Watch in Cancer Research...
The biotech bi‑weekly highlights a wave of new funding and tools, starting with Biohub’s $500 million five‑year Virtual Biology Initiative to generate global multimodal datasets for predictive biology. Zymo Research launched the Fecal Microbiome Discovery Grant to support early‑stage researchers, while...
Gaza’s Medical Evacuation Crisis Is Leaving Thousands Without Care
The health system in Gaza remains crippled after two years of conflict, leaving thousands of patients without essential care. The UN Health Cluster reports over 18,500 critical patients—4,000 of them children—still awaiting medical evacuation. From October 2023 to September 2025, only 7,802...
Qubit Pharmaceuticals Aims for Quadratic Speedup in Simulations
Qubit Pharmaceuticals and Singapore’s Centre for Quantum Technologies have deployed the first quantum Markov Chain Monte Carlo (qMCMC) algorithm on gate‑based quantum hardware. The two‑year partnership blends Qubit’s quantum chemistry know‑how with CQT’s expertise in circuit design, using Quantinuum’s H2...
Addressing the The Turbo-Cancer Epidemic
The article outlines the United States’ current cancer‑screening recommendations from USPSTF and the American Cancer Society, detailing age ranges and test types for breast, cervical, colorectal, lung, and prostate cancers. It also points out that routine screening is not advised...
The Myth of the Abortion Divide
The post examines long‑running U.S. polling on abortion, showing that about 51% of Americans label themselves pro‑choice while 43% call themselves pro‑life as of 2025. Gallup data reveal a steady split with the share of unsure respondents halving from 11%...
A Tale of Two Books: We Want Them Infected & In COVID’s Wake
The author contrasts his self‑published book *We Want Them Infected* with the Princeton‑authored *In COVID’s Wake*, noting that both address the U.S. pandemic response but diverge sharply in tone, reception, and political intent. *We Want Them Infected* compiles frontline accounts...
AI Moves From Proof-of-Concept to Proof-of-Return
McKinsey’s latest survey shows U.S. healthcare executives moving from experimenting with generative AI to demanding measurable returns. Half of the respondents have already deployed at least one GenAI use case, up from 25% two years ago, and 19% have adopted...
XPRIZE Healthspan Names Top 100 Teams Advancing Healthy Aging
The XPRIZE Healthspan competition announced its top 100 teams, spotlighting the core innovations of the 40 Milestone 1 award‑winning entrants. These teams are pursuing a spectrum of strategies—from mitochondrial‑targeted small molecules and metformin‑rapamycin combos to AI‑driven nutrition plans, senolytic drugs, and...
A Study in Regulatory Conservatism versus Clinical Innovation
At today’s ODAC meeting, the FDA will review AstraZeneca’s oral selective estrogen receptor degrader camizestrant for hormone‑receptor‑positive, HER2‑negative breast cancer with ESR1 mutations. Late‑stage data showed a 56% reduction in risk of disease progression and consistent safety, along with improved...
Cardiovascular Health 2026
Recent studies highlight pitavastatin’s pleiotropic benefits beyond LDL‑C reduction, including functional HDL elevation, enhanced cholesterol‑efflux capacity, and antioxidative actions in dyslipidemic patients. Pre‑clinical work shows the drug strengthens blood‑brain barrier integrity and mitigates lipopolysaccharide‑induced BBB dysfunction, suggesting neuroprotective potential. Real‑world...
FDA-Approved Marijuana Products and Those Subject to State-Issued Licenses Rescheduled; Marijuana Hearing Calendared; Dispensary Applications Accepted
Acting Attorney General Todd Blanche and the DEA issued a final rule that instantly reschedules FDA‑approved THC drug products and marijuana sold under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act. The rule aligns federal regulation...